{
  "main_header": {
    "sid": 333626,
    "name": "Novartis India",
    "stock_name": "Novartis India",
    "full_name": "Novartis India Ltd",
    "name_url": "stocks-analysis/novartis-india",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "786.80",
    "chg": -10.3,
    "chgp": "-1.29%",
    "dir": -1,
    "prev_price": "797.10",
    "mcapval": "1,963.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500672,
    "symbol": "NOVARTIND",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE234A01025",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "23.75 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novartis-india-333626-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Novartis India falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-novartis-india-fallingrising-3747260",
        "imagepath": "",
        "date": "2025-12-05 00:56:34",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Comparison</strong></p>\n<p>Novartis India’s shares have been on a downward trajectory, falling 1.79% over the past week compared to a more modest 0.53% decline in the Sensex. The trend extends over longer periods, with the stock losing 7.10% in the last month while the Sensex gained 2.16%. Year-to-date, the stock is down 13.34%, contrasting sharply with the Sensex’s 9.12% rise. Over the last year, the stock has plummeted 24.60%, whereas the benchmark index has appreciated by 5.32%. This underperformance is also evident over three and five-year horizons, where Novartis India’s returns lag significantly behind the broader market.</p>\n<p>On the day in question, the stock underperformed its sector by 1.77%, marking the third consecutive day of declines and touchi..."
      },
      {
        "title": "Novartis India Sees Revision in Market Evaluation Amidst Challenging Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novartis-india-downgraded-to-sell-by-marketsmojo-amid-weak-fundamentals-3736922",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NovartisIndia_mojoScore_3736922.png",
        "date": "2025-11-29 17:52:10",
        "description": "Novartis India has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. This adjustment comes amid a backdrop of subdued financial trends and technical indicators, impacting the pharmaceutical company's standing within its sector."
      },
      {
        "title": "Why is Novartis India falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-novartis-india-fallingrising-3676749",
        "imagepath": "",
        "date": "2025-11-06 22:05:50",
        "description": "As of 06-Nov, Novartis India Ltd is experiencing a decline in its stock price, currently at Rs 840.55, which reflects a decrease of Rs 17.5 or 2.04%. The stock has underperformed its sector by 1.27% today and has been on a consecutive downward trend for the last two days, resulting in a total drop of 3.71% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Over the past year, the stock has seen a significant decline of 22.19%, contrasting sharply with the Sensex, which has gained 3.65% in the same timeframe. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement.\n\nIn the broader market context, Novartis India's short-term performance has been notably weaker than the benchmark Sensex, which has only declined by 1.30%..."
      },
      {
        "title": "Is Novartis India overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novartis-india-overvalued-or-undervalued-3672831",
        "imagepath": "",
        "date": "2025-11-05 08:06:19",
        "description": "As of 4 November 2025, the valuation grade for Novartis India has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 19.90, a Price to Book Value of 0.27, and a PEG ratio of 0.91. Notably, the EV to EBITDA ratio stands at -40.09, indicating significant negative earnings before interest, taxes, depreciation, and amortization, which is an outlier compared to typical industry standards.\n\nIn comparison with peers, Novartis India’s PE ratio is lower than Sun Pharma's 35.41 and Divi's Lab's 78.59, both of which are classified as expensive. On the other hand, companies like Dr. Reddy's Labs, with a PE ratio of 17.36, and Cipla at 22.35, are more attractively valued. The recent stock performance shows that Novartis India has underperformed the Sensex over the past year, with a return of -19.75% compared to the Sensex's 5.94%, reinforcing the notion of its current fair valuation..."
      },
      {
        "title": "Is Novartis India overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novartis-india-overvalued-or-undervalued-3664853",
        "imagepath": "",
        "date": "2025-11-03 08:04:46",
        "description": "As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company appears to be overvalued based on its current financial metrics. The PE ratio stands at 20.06, while the PEG ratio is at 0.91, indicating a relatively high price compared to its earnings growth potential. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -40.77 and -39.92 respectively further suggest that the company's valuation is not justified by its earnings performance.\n\nIn comparison to peers, Novartis India’s valuation metrics are less favorable; for instance, Sun Pharma has a PE ratio of 35.35 and a PEG ratio of 4.03, while Cipla, which is rated attractive, has a PE ratio of 22.29. The significant divergence in these ratios indicates that Novartis India is not only overvalued relative to its peers but also struggling to deliver competitive returns, as evidenced by its year-to-date s..."
      },
      {
        "title": "Is Novartis India overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novartis-india-overvalued-or-undervalued-3663862",
        "imagepath": "",
        "date": "2025-11-02 08:04:40",
        "description": "As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company is currently overvalued based on its financial ratios, with a PE ratio of 20.06, a negative EV to EBIT of -40.77, and a ROE of only 1.38%. In comparison to peers, Sun Pharma has a significantly higher PE ratio of 35.35, while Dr. Reddy's Labs presents a more attractive PE of 17.34, highlighting Novartis India's relative overvaluation.\n\nThe company's performance has been underwhelming, with a year-to-date return of -5.85%, contrasting sharply with the Sensex's gain of 7.42% during the same period. This trend, along with the negative capital employed reflected in the EV ratios, suggests that Novartis India is not only overvalued but also struggling to generate adequate returns compared to its peers in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Novartis India overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novartis-india-overvalued-or-undervalued-3663277",
        "imagepath": "",
        "date": "2025-11-01 08:05:01",
        "description": "As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 20.06, a Price to Book Value of 0.28, and a PEG Ratio of 0.91. \n\nWhen compared to peers, Sun Pharma has a significantly higher PE ratio of 35.35, while Dr. Reddy's Labs, which is rated attractive, has a lower PE ratio of 17.34. Notably, Novartis India's stock has underperformed against the Sensex, with a year-to-date return of -5.85% compared to the Sensex's 7.42%. This further supports the conclusion that Novartis India is overvalued in the current market context...."
      },
      {
        "title": "Is Novartis India overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novartis-india-overvalued-or-undervalued-3660212",
        "imagepath": "",
        "date": "2025-10-31 08:08:09",
        "description": "As of 30 October 2025, Novartis India has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 19.98, a Price to Book Value of 0.27, and a PEG ratio of 0.91. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.63, while Dr. Reddy's Labs, which is considered attractive, has a lower PE ratio of 17.38.\n\nDespite the fair valuation, Novartis India has shown a negative return of -18.71% over the past year, contrasting with the Sensex's return of 5.58% during the same period. This underperformance may indicate potential challenges ahead, but the current ratios suggest that the stock is not overvalued relative to its peers in the pharmaceuticals and biotechnology industry...."
      },
      {
        "title": "Are Novartis India latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-novartis-india-latest-results-good-or-bad-3656315",
        "imagepath": "",
        "date": "2025-10-29 19:19:08",
        "description": "Novartis India has reported its financial results for Q2 FY26, presenting a mixed operational landscape. The company achieved a net profit of ₹24.22 crore, reflecting an 18.67% increase year-on-year, contrasting with a decline of 12.31% quarter-on-quarter. This indicates a positive trend compared to the same period last year, although the sequential performance raises concerns.\n\nRevenue for the quarter stood at ₹90.33 crore, marking a 3.71% increase year-on-year and a 3.18% increase from the previous quarter. This growth in revenue suggests resilience in core operations, yet it has not translated into enhanced profitability metrics. The operating profit, excluding other income, decreased to ₹23.88 crore, down 12.34% from the prior quarter, leading to a contraction in the operating margin to 26.44%, down from 31.11% in Q1 FY26. The PAT margin also saw a decline, indicating pressures on profitability despite ..."
      }
    ],
    "total": 194,
    "sid": "333626",
    "stock_news_url": "https://www.marketsmojo.com/news/novartis-india-333626"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (The Listing Regulations)",
      "datetime": "24-Nov-2025",
      "details": "Company letter dated February 20 2025 intimating the Stock Exchange on the order received on February 18 2025 for Service Tax Demand and Penalty for the period October 01 2014 to June 30 2017.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "24-Nov-2025",
      "details": "Company letter dated February 20 2025 intimating the Stock Exchange on the order received on February 18 2025 for Service Tax Demand and Penalty for the period October 01 2014 to June 30 2017.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "29-Oct-2025",
      "details": "Intimation of newspaper advertisement regarding the publication of unaudited financial results for the quarter and half-year ended September 30 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novartis India Ltd has declared <strong>500%</strong> dividend, ex-date: 23 Jul 25",
          "dt": "2025-07-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Novartis India falling/rising?

2025-12-05 00:56:34

Recent Price Movement and Market Comparison

Novartis India’s shares have been on a downward trajectory, falling 1.79% over the past week compared to a more modest 0.53% decline in the Sensex. The trend extends over longer periods, with the stock losing 7.10% in the last month while the Sensex gained 2.16%. Year-to-date, the stock is down 13.34%, contrasting sharply with the Sensex’s 9.12% rise. Over the last year, the stock has plummeted 24.60%, whereas the benchmark index has appreciated by 5.32%. This underperformance is also evident over three and five-year horizons, where Novartis India’s returns lag significantly behind the broader market.

On the day in question, the stock underperformed its sector by 1.77%, marking the third consecutive day of declines and touchi...

Read More

Novartis India Sees Revision in Market Evaluation Amidst Challenging Performance

2025-11-29 17:52:10

Novartis India has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment. This adjustment comes amid a backdrop of subdued financial trends and technical indicators, impacting the pharmaceutical company's standing within its sector.

Read More

Why is Novartis India falling/rising?

2025-11-06 22:05:50

As of 06-Nov, Novartis India Ltd is experiencing a decline in its stock price, currently at Rs 840.55, which reflects a decrease of Rs 17.5 or 2.04%. The stock has underperformed its sector by 1.27% today and has been on a consecutive downward trend for the last two days, resulting in a total drop of 3.71% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish sentiment. Over the past year, the stock has seen a significant decline of 22.19%, contrasting sharply with the Sensex, which has gained 3.65% in the same timeframe. Unfortunately, there is no information available regarding positive or negative factors that could further explain the stock's recent movement. In the broader market context, Novartis India's short-term performance has been notably weaker than the benchmark Sensex, which has only declined by 1.30%...

Read More

Is Novartis India overvalued or undervalued?

2025-11-05 08:06:19

As of 4 November 2025, the valuation grade for Novartis India has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 19.90, a Price to Book Value of 0.27, and a PEG ratio of 0.91. Notably, the EV to EBITDA ratio stands at -40.09, indicating significant negative earnings before interest, taxes, depreciation, and amortization, which is an outlier compared to typical industry standards. In comparison with peers, Novartis India’s PE ratio is lower than Sun Pharma's 35.41 and Divi's Lab's 78.59, both of which are classified as expensive. On the other hand, companies like Dr. Reddy's Labs, with a PE ratio of 17.36, and Cipla at 22.35, are more attractively valued. The recent stock performance shows that Novartis India has underperformed the Sensex over the past year, with a return of -19.75% compared to the Sensex's 5.94%, reinforcing the notion of its current fair valuation...

Read More

Is Novartis India overvalued or undervalued?

2025-11-03 08:04:46

As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company appears to be overvalued based on its current financial metrics. The PE ratio stands at 20.06, while the PEG ratio is at 0.91, indicating a relatively high price compared to its earnings growth potential. Additionally, the negative EV to EBIT and EV to EBITDA ratios of -40.77 and -39.92 respectively further suggest that the company's valuation is not justified by its earnings performance. In comparison to peers, Novartis India’s valuation metrics are less favorable; for instance, Sun Pharma has a PE ratio of 35.35 and a PEG ratio of 4.03, while Cipla, which is rated attractive, has a PE ratio of 22.29. The significant divergence in these ratios indicates that Novartis India is not only overvalued relative to its peers but also struggling to deliver competitive returns, as evidenced by its year-to-date s...

Read More

Is Novartis India overvalued or undervalued?

2025-11-02 08:04:40

As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company is currently overvalued based on its financial ratios, with a PE ratio of 20.06, a negative EV to EBIT of -40.77, and a ROE of only 1.38%. In comparison to peers, Sun Pharma has a significantly higher PE ratio of 35.35, while Dr. Reddy's Labs presents a more attractive PE of 17.34, highlighting Novartis India's relative overvaluation. The company's performance has been underwhelming, with a year-to-date return of -5.85%, contrasting sharply with the Sensex's gain of 7.42% during the same period. This trend, along with the negative capital employed reflected in the EV ratios, suggests that Novartis India is not only overvalued but also struggling to generate adequate returns compared to its peers in the pharmaceuticals and biotechnology sector....

Read More

Is Novartis India overvalued or undervalued?

2025-11-01 08:05:01

As of 31 October 2025, Novartis India has moved from a fair to an expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 20.06, a Price to Book Value of 0.28, and a PEG Ratio of 0.91. When compared to peers, Sun Pharma has a significantly higher PE ratio of 35.35, while Dr. Reddy's Labs, which is rated attractive, has a lower PE ratio of 17.34. Notably, Novartis India's stock has underperformed against the Sensex, with a year-to-date return of -5.85% compared to the Sensex's 7.42%. This further supports the conclusion that Novartis India is overvalued in the current market context....

Read More

Is Novartis India overvalued or undervalued?

2025-10-31 08:08:09

As of 30 October 2025, Novartis India has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 19.98, a Price to Book Value of 0.27, and a PEG ratio of 0.91. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.63, while Dr. Reddy's Labs, which is considered attractive, has a lower PE ratio of 17.38. Despite the fair valuation, Novartis India has shown a negative return of -18.71% over the past year, contrasting with the Sensex's return of 5.58% during the same period. This underperformance may indicate potential challenges ahead, but the current ratios suggest that the stock is not overvalued relative to its peers in the pharmaceuticals and biotechnology industry....

Read More

Are Novartis India latest results good or bad?

2025-10-29 19:19:08

Novartis India has reported its financial results for Q2 FY26, presenting a mixed operational landscape. The company achieved a net profit of ₹24.22 crore, reflecting an 18.67% increase year-on-year, contrasting with a decline of 12.31% quarter-on-quarter. This indicates a positive trend compared to the same period last year, although the sequential performance raises concerns. Revenue for the quarter stood at ₹90.33 crore, marking a 3.71% increase year-on-year and a 3.18% increase from the previous quarter. This growth in revenue suggests resilience in core operations, yet it has not translated into enhanced profitability metrics. The operating profit, excluding other income, decreased to ₹23.88 crore, down 12.34% from the prior quarter, leading to a contraction in the operating margin to 26.44%, down from 31.11% in Q1 FY26. The PAT margin also saw a decline, indicating pressures on profitability despite ...

Read More

View All News